<DOC>
	<DOCNO>NCT00500747</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , effectiveness vaccine ( HCV E1/E2/MF59 vaccine ) hepatitis C ( HCV ) . The vaccine give 60 healthy adult volunteer ( age 18-45 year ) study compare immune system ( body 's protective response ) response HCV E1/E2 vaccine give different dosage level : 4 microgram , 20 microgram , 100 microgram MF59 adjuvant ( substance improve vaccine effectiveness ) . The volunteer assign randomly ( chance ) 1 4 different group . Volunteers group receive shot vaccine placebo ( shot medication ) . Participants involve study related procedure 71 week , include blood sample , record symptom diary card , 4 vaccine placebo injection .</brief_summary>
	<brief_title>Chiron Corp HCV E1/E2 Vaccine</brief_title>
	<detailed_description>Hepatitis C virus ( HCV ) emerge significant public health concern throughout world . Its estimate prevalence US 1.5 percent , 2.7 million people chronic infection . As many 170 million people may chronic HCV infection worldwide . The Centers Disease control currently estimate 40,000 HCV infection occur yearly US , current infection acquire illegal injection drug use . It estimate 70 percent infect develop chronic liver disease . The purpose study conduct Phase I vaccine trial novel vaccine , HCV E1E2/MF59 . The study objective evaluate safety , tolerability , immunogenicity HCV E1E2/MF59 vaccine administer healthy adult subject compare immune response HCV E1E2 vaccine give 4 , 20 , 100 mcg MF59 adjuvant . Sixty healthy adult , age 18-45 , randomize receive one 3 different dos vaccine placebo . Each subject receive vaccine 0 , 4 , 24 , 48 week . Study procedure include blood sample collection question regard risk factor acquire HCV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Healthy , hepatitis C virus ( HCV ) negative . 1845 year old healthy adult . Insufficient data available adult judge risk child . In good general health determine medical history , physical examination follow screen lab : Complete Blood Count ( CBC ) : Total WBC ( White Blood Cell ) : 3.514 thousand/microliter ( MCL ) ; Hemoglobin ( Hgb ) : Men : 12.218 g/dl Women : 10.517 g/dl . Creatinine : Men : le equal 1.4 mg/dl ; Women : less equal 1.2 mg/dl . Glucose : 50 mg/dl less equal 109 mg/dl . Alanine Aminotransferase ( ALT ) : Men 260 units/litre ( U/I ) : Women : 340 U/I . Aspartate Aminotransferase ( AST ) : Men : 250 U/I , Women 235 U/I . Total bilirubin : Men : le equal 1.5 mg/dl : Women : less equal 1.3 mg/dl . Urinalysis : negative trace protein , negative glucose , less equal 3 Red Blood Cells ( RBC ) /High Power Field ( HPF ) less equal 5WBC/HPF ( nonmenstruating female ) . Negative serum cryoglobulin Hepatitis B : negative Hepatitis B Surface Antigen ( HBsAg ) ( use standard Food Drug Administration FDA approve test , e.g . Abbott Organon ) . Hepatitis C : AntiHepatitis C Virus ( HCV ) negative HCV Ribonucleic Acid ( RNA ) negative ( use standard FDA approve test , e.g . Abbott Organon ) . HIV ELISA negative ( use standard FDA approve test , e.g . Abbott Organon ) ( Written inform consent HIV antibody test obtain obtain HIV sample . ) Note : HIV vaccine volunteer test positive HIV ELISA HIV western blot test due receipt HIV vaccine may participate test negative HIV DNA Polymerase Chain Reaction ( PCR ) . Negative urine pregnancy test ( female child bear potential ) obtain screen day immunization . The ability understand sign write informed consent document . Available 16 month first injection followup may complete . Diabetes . Cancer squamous cell skin cancer excise . History myocardial infarction arrhythmia require hospitalization . Syncope require hospitalization . Unconsciousness simple concussion . Seizures febrile seizure child &lt; 5 year age . Current liver disease ( include Gilbert 's disease ) . Autoimmune disease ( include thyroid disease vitiligo ) . Splenectomy . Uncontrolled hypertension [ blood pressure ( BP ) &gt; 150/90 ; antihypertensive medication acceptable ) . Subjects identifiable highrisk behavior HCV infection characterize following : injection drug use ( IVDU ) cocaine snort within last year . Subject tattoo body pierce within past 6 month and/or plan acquire tattoo body pierce period study . Subjects tattoos bilateral site needle insertion . Pregnant lactating woman . Women child bear potential must use effective contraception least 30 day prior initial immunization , unless religious , social , medical reason intend child practice sexual abstinence . Subjects use birth control must agree entire 64 week study period . Acceptable method birth control define hormonal contraceptive , intrauterine device ( IUD ) , diaphragm spermicide , condom , vasectomize partner abstinence . Concomitant drug exclusion : corticosteroid ( intranasal spray topical cream ) know immunosuppressive drug ( chemotherapy cancer ) ; experimental agent ; antituberculosis medication , e.g. , isoniazid ( INH ) . Personnel engage blind study . Subjects reason adhere schedule protocol enrol study . Subjects judgment investigator would good candidate due medical , psychiatric , social condition may interfere serve contradiction adherence study protocol . Subjects sex partner know active Hepatitis B virus ( HBV ) , HCV , HIV infection . Currently abuse alcohol . Alcohol abuse define require hospital admission detoxification therapy alcohol use significant impact personal relationship ability work productively . Not accessible telephone pager . Live attenuate immunization within 4 week vaccination . Inactivated immunization within 2 week vaccination . Febrile illness within 3 day study entry base verbal report subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>hepatitis C , HCV , vaccine , recombinant vaccine , adjuvant</keyword>
</DOC>